Vincent LoPriore becomes Hepion reporting insider

Hepion Pharmaceuticals, Inc. filed an initial Form 3 identifying Vincent S. LoPriore as an insider.

Accepted by SEC EDGAR 03/18/2026 - 05:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. filed an initial Form 3 identifying Vincent S. LoPriore as an insider. He is listed as both a director and an officer, serving as Executive Chairman. The filing does not report any share purchases, sales, or other insider transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Hepion (HEPA) disclose about Vincent LoPriore in this Form 3?

The Form 3 identifies Vincent S. LoPriore as an insider of Hepion Pharmaceuticals, Inc. He is reported as both a director and an officer, holding the title of Executive Chairman, establishing his status as a reporting person under SEC rules.

Does Vincent LoPriore buy or sell Hepion (HEPA) shares in this Form 3?

This Form 3 does not report any purchases, sales, gifts, or other transactions in Hepion Pharmaceuticals, Inc. shares by Vincent S. LoPriore. The transaction summary shows zero buy, sell, exercise, or other transaction entries for this initial beneficial ownership statement.

What insider role does Vincent LoPriore hold at Hepion (HEPA)?

Vincent S. LoPriore is reported as both a director and an officer of Hepion Pharmaceuticals, Inc. His officer title is Executive Chairman, indicating a senior leadership position with board responsibilities and executive authority within the company’s governance structure.

Is this Hepion (HEPA) Form 3 focused on derivative securities?

The Form 3 does not list any derivative securities for Vincent S. LoPriore. The derivative summary section is empty, and the derivative transaction count is zero, indicating no options, warrants, or similar instruments are reported in this particular filing excerpt.

What does the transaction summary indicate in Hepion (HEPA) Vincent LoPriore’s Form 3?

The transaction summary shows zero buys, zero sells, and no exercises or gifts for Vincent S. LoPriore. Net buy-sell direction is neutral, confirming this Form 3 serves as an initial status report rather than documenting any recent trading activity in Hepion shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LoPriore Vincent S

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Vincent S. LoPriore	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)